PomegraXencor Stock Jumps 20% After Kidney Cancer Trial Data
Why did Xencor stock jump 20%?
Xencor (XNCR) stock rose 20% to $30.18 on Monday after its kidney cancer drug XmAb819 showed a 45.5% response rate in trial data, sending shares to a 52-week high.
Key numbers
| Confirmed response rate | 45.5%5 of 11 patients |
|---|---|
| Disease control rate | 81.8%400 µg/kg dose |
| Share move Monday | +20% to $30.18Reports range 20–31% intraday |
| Progression-free at 6 months | 82%Median not reached |
| Grade 3+ side effects | 82.4%68 patients; [2] cites 72.1% |
| Tivozanib response rate (per [2]) | 10.5%Separate TiNivo-2 trial |
What happened
Xencor (XNCR) stock rose 20% to $30.18 on Monday after its kidney cancer drug XmAb819 showed a 45.5% response rate in trial data, sending shares to a 52-week high. Of 11 patients given the dose Xencor picked, 5 had confirmed tumor shrinkage, and the cancer stopped growing in 81.8% of them. Xencor says it will talk to the FDA in the first half of 2027 about accelerated approval, a faster route to market for promising drugs. The group is small, so larger trials must confirm the results.
Why it matters
Xencor's drug XmAb819 could give kidney cancer patients a new option after other treatments stop working. Its 45.5% response rate is well above the 10.5% reported for tivozanib, an existing treatment, in a separate study, though the two trials are not directly comparable. Most patients also had serious side effects, so safety will matter as testing grows.
Who this affects
- MarketneutralLow impact
- Limited effect beyond Xencor holders and other biotech stocks.
- CompanybullishHigh impact
- Xencor shareholders gain; drug moves toward late-stage testing.
- CompetitorsbearishLow impact
- Existing kidney cancer treatments face a stronger challenger if confirmed.
- IndustrybullishMedium impact
- Boosts hopes for T-cell engager drugs in solid tumors.
Xencor's XmAb819 vs Tivozanib
| XmAb819 (Xencor)XNCR | 45.5% | 82% | 11 |
|---|---|---|---|
| Tivozanib (TiNivo-2 trial)— | 10.5% | 41% | — |
As of 2026-10-26
How we got here
Data cut-off for the updated XmAb819 kidney cancer results.
Xencor reports 45.5% response rate and picks 400 µg/kg as planned Phase 3 dose.
Shares jump about 20% to a 52-week high on the data.
What to watch
- Xencor's planned FDA talks on a possible accelerated approval path for XmAb819H1 2027
- Full 400 µg/kg dataset from the larger group of patientsH1 2027
- Start of randomized trial comparing XmAb819 with tivozanibQ4 2027
Educational content only. Not investment advice.
More briefsAll briefs →
Shekel Faces 3% Swing as Israel Votes in Tight Election
Shekel (USD/ILS) is up 25% since Oct. 2023 as betting markets give Eisenkot 58% odds to Netanyahu's 27%.
10-Year Treasury Yield Holds Near 5% as Fed Hold Looms
The 10-year Treasury yield (US10Y) is 4.99% and the yen is near 157.5 per dollar before Fed and BOJ meetings.
Boeing Stock Heads Into Earnings Expecting 21-Cent Loss
Boeing (BA) reports before the bell with $330.5M free cash flow expected, a key test of its turnaround